Multi-cancer early detection using cell-free DNA methylome analysis
Active Cooperative Agreement Awarded Last action
- Award ID
- U01CA285010
- Recipient
-
University Of California, LOS Angeles UEI RN64EPNH8JC6 Part of State Of California Controllers Office
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,589,416
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date 63% complete
- Place of performance
- Los Angeles, CA 90095, USA
Award details come from USAspending.gov.
Description
- Abstract
- Detecting cancer early is the best way to fight against cancer. The development of the multi-cancer early detection (MCED) liquid biopsy tests holds great promise for integrating early cancer detection into routine clinical care. However, the current MCED tests have unsatisfactory performance for early-stage cancers. Recently, we have developed a sensitive and cost-effective technology, named cell-free DNA methylome sequencing (CFMETHYL-SEQ), which uses the cell-free DNA methylome for early cancer detection. CFMETHYL-SEQ provides >12-fold enrichment over whole genome bisulfite sequencing in CPG islands. We performed the proof- of-principle study by applying CFMETHYL-SEQ to a cohort of colon, liver, lung, and stomach cancer patients and controls, and obtained promising results in detecting and locating these cancer types. Here, we will further improve the CFMETHYL-SEQ technology and apply IT to detect and locate colon, gastric, liver, and lung cancer. We will validate this MCED test in multiple clinical cohorts. Our multidisciplinary team proposes the following aims: (1) continued improvement of the CFMETHYL-SEQ assay for early cancer detection. (2) continued improvement of our computational method to analyze the cfdna methylome assay data. (3) clinically validate the cfdna methylome assay as an MCED assay with colon/gastric/liver/lung cancers as the first indications. (4) contribute to collaborative trans-consortium activities. We have a long-standing collaboration with the industry partner, earlydiagnostics, which will optimize the CFMETHYL-SEQ assay to facilitate its clinical adoption and implement the computational algorithm in a secure cloud computing platform to facilitate data sharing and decentralized testing.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $925,584 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $879,305 | |
| Amendment | $879,305 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $952,611 | |
| Original award | $952,611 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Earlydiagnostics Inc. | $324,051 | |
| The Univeristy Of Texas M.d. Anderson Cancer Center | $483,931 |
Quick answers
Who received award U01CA285010?
U01CA285010 was awarded to University Of California, LOS Angeles by National Cancer Institute (National Institutes of Health) on September 19, 2023.
How much is award U01CA285010 worth?
$4,589,416 has been obligated on U01CA285010.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award